7th International Conference on

12^{TH} World CADD & Drug Delivery Summit

CLINICAL TRIALS

September 24-26, 2018 | Chicago, USA

Innovative approaches for secure, modern collaborative drug discovery

Luke S Fisher, Barry Bunin, Charlie Weatherall, Kellan Gregory and Marc Navre Collaborative Drug Discovery, Inc, USA

Currently, infectious diseases of the developing world (e.g., malaria, tuberculosis) represent a global health challenge of the 21st century and require new approaches that would allow scientists to do research more effectively. As a result of the development of web-database technologies (CDD Vault^{*}), a collaborative approach to research on antibiotics and infectious diseases for global health has emerged. The major components of effective scientific-community based research include: (1) unifying goal or focus on common therapeutic areas/diseases; (2) multiple research areas/expertise; (3) uniform database platform for effective data accumulation and management; (4) easy access and sharing of information; (5) potential for unlimited growth. The Collaborative Drug Discovery (CDD) Vault^{*} was built by utilizing innovative web technologies in order to provide a platform that allows scientists to archive, mine, and securely share research data with a focus on global collaborative R&D. This new collaborative technology allows researchers to build up networks of technical experts around therapeutic or target areas thus advancing research facilitating the discovery of new drug candidates. It also allows scientists to speed up research by sharing unpublished data providing new hope in the race to overcome drug resistance. An example illustrating how potential chemosensitizers that address chloroquine resistance could be identified by using the CDD Vault^{*} database platform is presented.

Biography

Luke S Fisher brings twenty years of experience in scientific informatics solutions. Managing Pre-Sales, Post-Sales and working in Account Management has expanded my domain knowledge of scientific informatics and provided me the ability to maintain a successful track record. He have covered a broad range of clients including the world's leading pharmaceutical, biotech, agricultural, chemicals, academic and government labs. He have extensive experience in scientific software solutions from the smaller scale deployment of point solutions like molecular modeling packages to the larger enterprise scale of ELNs, scientific workflow technologies, data content, analysis and visualization. It also includes managing the support complexity of software integration strategies based on numerous mergers and acquisitions...

Notes: